top of page

TOP PHARMACEUTICAL COMPANIES BY REVENUES IN 2022

Updated: Apr 28

REVENUES OF TOP BIOPHARMACEUTICAL COMPANIES - 2022

1 CHF = 1.01 USD, 1 GBP = 1.16USD; 1EUR= 0.99 USD; 1DKK = 0.13 USD; 1 JPY = 0.0075 USD

Merck revenues include only pharmaceuticals (excluding animal health)


Top pharmaceutical companies by revenues in 2022 by different segments
Top pharmaceutical companies by revenues in 2022

CLICK HERE TO CHECK TOP PHARMACEUTICALS BY REVENUES IN 2023

 

PFIZER

Q1 REVENUES

Pfizer reported revenues of $25.7 billion in the first quarter of 2022, reflecting operational growth of 82%. The revenues from the vaccines segment were $14.94 billion, the hospital segment was $3.19 billion, the oncology segment was $2.97 billion, and immunology was $820 million.

The revenue drivers of the company were Comirnaty ($13.23 billion), Prevnar family ($1.57 billion), Paxlovid ($1.47 billion), Eliquis ($ 1.79 billion), and Ibrance ($1.24 billion).


Also read: FDA Drug Approvals


H1 REVENUES

Pfizer reported revenues of $27.7 billion in the second quarter of 2022. Paxlovid and Comirnaty primarily drove the revenues.

The total revenues in the first half of 2022 were $53.4 billion. The vaccine segment contributed $25.4 billion, the hospital products segment (including Paxlovid) contributed $12.9 billion,

In the first half of 2022, Comirnaty revenues were $22.07 billion, Paxlovid was $9.6 billion, Ibrance was 2.5 billion, and Eliquis was $3.5 billion. Eliquis revenues increased by 13%, but Ibrance revenues dropped by 4%, and Xeljanz revenues reduced by 29%.


Also read: NICE Assessment Outcomes


9 MONTHS

Pfizer announced the revenues of the third quarter, reporting revenues of $22.6 billion, revenues declined by 2% versus last year.

In the first nine months, the revenues were $76 billion. The revenues from Comirnaty were $26.5 billion, Paxlovid was $17 billion, Eliquis was $5 billion, Prevanar family was $4.6 billion, Ibrance was $3.8 billion, and Xeljanz was $1.3 billion.